WINTON GROUP Ltd Acquires New Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

WINTON GROUP Ltd bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,500 shares of the company’s stock, valued at approximately $6,408,000.

Several other hedge funds and other institutional investors have also bought and sold shares of IDXX. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories in the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter valued at about $31,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $41,000. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on IDXX shares. Piper Sandler raised their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $417.71 on Thursday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a market cap of $33.86 billion, a PE ratio of 39.15, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company’s 50 day moving average is $437.26 and its 200 day moving average is $443.87.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.